PreferredStockChannel
Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Sat, April 1, 4:53 PM
| This Slide: #483 of 609 |
Slide #483. Cell Therapeutics, Inc. — Preferred Stock Offering
Company:
Cell Therapeutics, Inc. (NASDAQ:CTIC)
Date announced:
9/12/2013
Shares Offered:
15,000
Preferred Stock Offering Details:
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering"). The net proceeds from the Offering, after deducting estimated offering expenses, will be approximately $14.8 million.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
Open the CTIC Page at Preferred Stock Channel »
|
|||||||||||||||||||||
|
|
Open the CTIC Page at Preferred Stock Channel (in a new window) »
 Free CTIC Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
Avg. Broker Rec.
 
|
Strong Buy (3.86 out of 4) 74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
 |
